Stitch Fix Inc vs Twist Bioscience Corp — how do they compare? Stitch Fix Inc trades at $2.9 (market cap $385.60M), while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: Twist Bioscience Corp is far larger — about 21.4× Stitch Fix Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| SFIX | TWST | |
|---|---|---|
Market Cap | $385.60M | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $5.80 | $153.10 |
52-Week Low | $2.89 | $24.16 |
Enterprise Value | $273.32M | $8.18B |
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $2.97, down 2.62% on the day, reflecting ongoing investor caution despite recent operational improvements. The stock is technically bearish with key moving averages signaling selling pressure, while fundamentals show a narrowing net loss margin to -2.27% in 2025 from -9.64% in 2024, alongside a low price-to-sales ratio of 0.3. Recent news highlights AI-driven personalization efforts and exclusive brand collaborations aimed at boosting client engagement and revenue per user.
The outlook remains mixed; cost controls and revenue stabilization offer a path to profitability, but persistent net losses and competitive pressures pose risks. Analyst sentiment is cautious with a 63.64% hold rating, suggesting investors await clearer signs of a sustained turnaround before committing capital.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Trailing returns across standard periods
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →